Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.

Breast cancer research and treatment - 4 Jun 2026

Gong Cynthia L, Chavez-MacGregor Mariana, Xu Xiaoqing, Park Leah, Elsea David, Katsandres Sarah, Migliaccio-Walle Kristen, Veenstra David L

Abstract excerpt

PURPOSE: Novel drugs for metastatic breast cancer (mBC) can provide patients not only with improved survival but also the opportunity to benefit from future treatment innovations, a concept referred to as real option value (ROV). Quantifying the ROV of first-line (1L) olaparib may help clinicians and patients better understand the additional value increased survival provides through access to future innovative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Markov Chains

Share to Neoplasm Metastasis

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 42243369
DOI: 10.1007/s10549-026-07988-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.PMID 42243369Read ↗

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.Semantic proximity Read ↗

Cost-utility analysis of genomic profiling in early breast cancer in ColombiaSemantic proximity Read ↗

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity Read ↗

Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.Semantic proximity Read ↗

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma.Semantic proximity Read ↗

Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?Semantic proximity Read ↗

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.Semantic proximity Read ↗

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read ↗

Ibrutinib versus bendamustine plus rituximab for first-line treatment of older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: A lifetime economic research studySemantic proximity Read ↗

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesSemantic proximity Read ↗

Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysisSemantic proximity Read ↗

Clinical and Economic Impact of ‘ROS1-Testing’ Strategy Compared to a ‘No- ROS1-Testing’ Strategy in Advanced NSCLC in SpainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.